The general scope of the book is the patentability and morality of human embryonic stem cell
research in US EU and China. The book observes fraudsters operate unsafe human embryonic stem
cell therapies and officialdom turns a blind eye to the immoral human embryonic stem cell
research in China. The book highlights that both patent control and federal funding control are
inefficient and ineffective way to monitoring human embryonic stem cell research. The book
finally proposed an approach for china to regulating human embryonic stem cell
research-regulating research itself at the reconciled international regime. The potential
reader includes academics and practitioners dealing with intellectual property patent law and
stem cell inventions. The topic discussed will also be interesting to a broad readership
including experts regulators policy makers and medical researchers in both ethical and legal
disciplines in the field of embryonic stem cell research.
